EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer

Kun Ye iD, Ming Xiao, Zitaiyu Li, Kancheng He, Jinhua Wang, Liang Zhu, Wei Xiong, Zhaohui Zhong, Yuxin Tang

Cancer Medicine · 2023-02 · 12 (4) · 4206-4217

DOI: 10.1002/cam4.5284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.10.2022. Verfasst von Kun Ye und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Systemic Inflammatory Response Index (SIRI) is a novel prognostic biomarker based on peripheral blood counts of neutrophils, monocytes, and lymphocytes. Recent evidence suggests that it is associated with poor prognosis in various cancers. However, the predictive value of the SIRI in non‐muscle‐invasive bladder cancer (NMIBC) patients treated with intravesical Bacillus Calmette‐Guerin (BCG) immunotherapy remains elusive. Therefore, this study aimed to evaluate the potential of SIRI as a prognostic factor in these patients.

Methods

A total of 540 patients with NMIBC who underwent BCG immunotherapy following transurethral resection of bladder tumor (TURBT) were enrolled in this study. Using receiver operating characteristic (ROC) curves and the Youden index, patients were divided into high and low SIRI groups based on the cutoff values. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of BCG non‐response. Thereafter, propensity score matching (PSM) was used to eliminate bias due to confounding factors between the low and high SIRI groups. Finally, the Kaplan–Meier method was used to compare recurrence‐free survival (RFS) and progression‐free survival (PFS) between the two groups.

Results

Multivariable logistic regression analysis revealed that high SIRI ( p = 0.001), high MLR ( p = 0.015), and high tumor pathological T stage ( p = 0.015) were significantly correlated with non‐response to BCG therapy. In addition, both RFS and PFS were shorter in the high SIRI group than in the other group before and after PSM (both p < 0.05). Collectively, our results indicate that the combination of tumor pathological T staging and the SIRI can enhance the predictive power of BCG response.

Conclusion

Pretreatment peripheral blood SIRI can be employed to predict the response to BCG immunotherapy and the prognosis of NMIBC patients. Taken together, the combination of T stage and SIRI demonstrated robust performance in predicting the response to BCG immunotherapy in NMIBC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsHumansPrognosisBCG VaccineInflammationImmunotherapyRetrospective Studies

Stichwörter der Autor:innen

BCG responseNMIBCbiomarkersinflammationsystemic inflammatory response index

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China.
  • Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Kun Ye

Zitieren

APA

Ye, K., Xiao, M., Li, Z., He, K., Wang, J., Zhu, L., Xiong, W., Zhong, Z., & Tang, Y. (2023). Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer. Cancer Medicine, 12(4), 4206-4217. https://doi.org/10.1002/cam4.5284

Vancouver

Ye K, Xiao M, Li Z, He K, Wang J, Zhu L, et al. Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer. Cancer Medicine. 2023;12(4):4206-4217. doi:10.1002/cam4.5284

BibTeX
@article{Ye2023,
  author = {Ye, Kun and Xiao, Ming and Li, Zitaiyu and He, Kancheng and Wang, Jinhua and Zhu, Liang and Xiong, Wei and Zhong, Zhaohui and Tang, Yuxin},
  title = {Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {4206--4217},
  doi = {10.1002/cam4.5284}
}
Kostenlos starten →